Genetic associations between type 1 diabetes and alleles at the HLA class II locus DPB1 have been previously reported. Observed associations could be due to variation in the DPB1 locus itself or to linkage disequilibrium (LD) between DPB1 alleles and other susceptibility loci. One measure of whether the association of an allele with a disease reflects a true effect of the locus or is simply due to LD is the observation of that association in multiple ethnic groups. Previous type 1 diabetes associations have been reported for DPB1*0301 and DPB1*0202 (predisposing) and for DPB1*0402 (protective). In this study, results are reported from testing these associations in three different sample sets: 1) Puerto Rican case and control subjects, 2) Mexican-American simplex families, and 3) high-risk (DR3/DR4) individuals with and without an affected relative. DPB1*0301 was associated in all three groups, even after accounting for LD with DRB1-DQB1. DPB1*0202 and DPB1*0402 were positively and negatively associated, respectively, in two of the three populations. These results suggest that the observed DPB1 associations, especially that of the DPB1*0301 allele, with type 1 diabetes are likely to be true associations. This supports the concept that multiple genes in the HLA region can affect type 1 diabetes susceptibility.

Type 1 diabetes is a multifactorial autoimmune disease with both environmental and genetic susceptibility (13). The HLA region of chromosome 6p21 is estimated to contribute >50% of the total genetic risk (4,5). Association studies have demonstrated that multiple loci within the HLA region appear to contribute to disease risk (1,68).

The genes encoding DR and DQ are well established to have the greatest genetic effect on type 1 diabetes susceptibility. The DPB1 gene encodes the β-chain of the DP molecule, which has similar structure and function to DR and DQ. Genetic associations of DPB1 alleles with type 1 diabetes susceptibility have been reported (5,712), with one report showing no detectable association (13). Type 1 diabetes associations of DPB1 alleles could either be due to changes in the encoded polypeptide chain or to linkage disequilibrium (LD) between DPB1 alleles and other susceptibility loci.

Positive type 1 diabetes association of DPB1*0301 has been reported in several studies in which the LD of DPB1 with DR-DQ genes has been taken into account (7,10,11). An increased risk due to allele DPB1*0202 and a decreased risk due to allele DPB1*0402 have also been reported (10,11).

This study examines DPB1 association with type 1 diabetes in three different settings: 1) a case-control study from Puerto Rico, 2) transmission disequilibrium test analysis of Mexican-American type 1 diabetic simplex families, and 3) comparison of HLA high-risk (DR3/DR4-DQB1*0302; DR4≠DRB1*0403) individuals with and without an affected first-degree relative, collected as part of the Diabetes AutoImmunity Study of the Young (DAISY). The hypothesis underlying the DAISY data in this study is that DPB1 allele frequency differences may at least partially account for the higher rate of autoimmunity and type 1 diabetes observed in high-risk, first-degree relatives compared with high-risk individuals without a first-degree relative (see below). These data demonstrate reproducibility of associations among ethnic groups and support a role for the DPB1 locus as a risk factor for type 1 diabetes.

Previously observed disease associations for DPB1*0301 and DPB1*0202 (positive) and DPB1*0402 (negative) with type 1 diabetes (5,7,912) were tested in three distinct sample sets with three different study designs (described in research design and methods).

Table 1 shows the results of allele frequency determination for the DPB1 locus in 91 patients and 82 control subjects from Puerto Rico and in 84 Mexican-American simplex families. In the Puerto Rican data, significant association was seen for DPB1*0301 (P = 0.024). The data were suggestive, although not statistically significant, of a positive disease association with the allele DPB1*0202 (P = 0.058). DPB1*1701 also appeared positively associated with type 1 diabetes in these data (P = 0.009); however, negative type 1 diabetes association for DPB1*1701 was previously reported (10) for Caucasian families. This difference may be attributable to differences in LD patterns between populations. For Mexican-American families, expected associations were observed: positive association for DPB1*0202 (P = 0.027) and DPB1*0301 (P = 0.002) and negative association for DPB1*0402 (P = 0.017).

Because of the strong LD within the HLA region, some apparent associations may simply be “bystander” effects caused by LD with highly predisposing or protective DR- and DQ-encoding loci. DRB1 and DQB1 genotypes were determined for all individuals in both datasets. Values were calculated for LD between DRB1-DQB1 haplotypes and DPB1 alleles (Table 2).

In both the Mexican-American and the Puerto Rican populations, DPB1*0401 was in positive LD with DRB1*0101-DQB1*0501. Other LD patterns differed between the two populations. DPB1*0402 was in positive LD with DRB1*0701 in the Puerto Rican data but in negative LD with DRB1*0701 in the Mexican-American data. DPB1*0402 had a clear protective effect among Mexican Americans, but the reduced frequency in patients was not significant in Puerto Ricans. The very high positive LD with DRB1*0701 (type 1 diabetes protective) may reduce the power to detect any additional protective effect of DPB1*0402 in Puerto Ricans. No significant LD was observed for DPB1*0202 in either population, although this may be attributable to a lack of power resulting from small sample size rather than the absence of LD. DPB1*0202 is found primarily on DR3 haplotypes in Caucasians (10); it is found on multiple haplotypes in Filipinos, where it shows a strong type 1 diabetes association (8). DPB1*0301 exhibited LD with DRB1*1302-DQB1*0604 (neutral to slightly predisposing) in the Puerto Rican data but showed no significant LD in the Mexican-American data. This suggests that DPB1 associations observed in these data are not attributable solely to LD of DPB1 alleles with DRB1-DQB1 haplotypes.

Revised expected values for all DPB1 alleles were calculated based on the LD results. Deviation from the null hypothesis was tested (Table 3). For both populations, results for DPB1*0301 and DPB1*0202 still suggest a positive type 1 diabetes association after correction for LD. The novel negative association of DPB1*1701 with type 1 diabetes in the Puerto Rican data also remains significant (P = 0.011) but may be spurious or unique to this population. The protective effect of DPB1*0402 in the Mexican-American data remains (P = 0.012) after LD correction.

Table 4 shows a comparison of DPB1 allele frequencies for the two groups of DAISY samples. High type 1 diabetes risk individuals (DR3/4-DQB1*0302; DR4≠DRB1*0403) were selected from both the General Population Cohort (GPC) and the Sibling-Offspring Cohort (SOC) (see research design and methods). This study design differs from the others in that the comparison is not between patients and control subjects but between HLA-matched individuals with or without a type 1 diabetic relative. The observed higher type 1 diabetes risk for high-risk SOC subjects than for high-risk GPC subjects leads to the testable hypothesis that the SOC subjects are enriched in non–DR-DQ susceptibility alleles.

The data show that DPB1*0301 is significantly overrepresented in the SOC (P = 0.04) compared with the GPC, whereas DPB1*0402 is underrepresented in the SOC (P = 0.002) compared with the GPC, consistent with previous observations for these alleles. DPB1*0202 was rare and did not differ significantly between the two populations. To address issues of ethnic differences between the GPC and SOC, the Caucasian subset of these samples was analyzed separately. In the Caucasian-only sample, DPB1*0301 remained overrepresented in the SOC, although not significantly (P = 0.087), suggestive of a positive type 1 diabetes association. The underrepresentation of DPB1*0402 in the SOC remained significant (P = 0.01) in the Caucasian set, supporting a protective effect on type 1 diabetes susceptibility.

The HLA class II DR- and DQ-encoding loci are strongly associated with type 1 diabetes susceptibility, but even the highest-risk DR-DQ genotype (DR3/DR4-DQB1*0302) only predicts an ∼7% risk of disease in the general population. Increasing the predictive value of genetics for type 1 diabetes susceptibility requires identification of other risk factors. Because effects of other genetic susceptibility loci are expected to be modest, associations of such loci are difficult to identify and replicate and can be confounded by DR-DQ heterogeneity. The frequency of the DR3/DR4 heterozygous genotype is too low in the Mexican-American and Puerto Rican control groups to make any risk estimates based on DPB1 subgroups; the frequency of DR4/DRX genotypes was sufficient. The data suggest that for DR4/DRX individuals (X ≠ DR3 or DR4), the added risk of carrying at least one copy of either DPB1*0202 or DPB1*0301 increases the probability of developing type 1 diabetes by 60% in the Puerto Ricans and 104% in the Mexican Americans. In addition, not carrying DPB1*0402 increases the probability of developing type 1 diabetes by 16% in the Puerto Ricans and 83% in the Mexican Americans (data not shown).

Whether the DP molecules themselves directly affect type 1 diabetes susceptibility remains in question. A recent study (12) showed DPB1 associations consistent with those seen in the present study, but the authors attributed the associations to LD of DPB1 with other genetic loci in the HLA region, citing LD of DPB1 with a microsatellite marker, located beyond the HLA region and not in proximity to any candidate functional gene. The protein encoded by the DPB1 locus has a similar function to that of DR and DQ, and DPB1 associations have been replicated in multiple studies, supporting the notion that polymorphism in the DPB1 locus itself may affect type 1 diabetes susceptibility.

The results reported here support previous reports of effects for three DPB1 alleles, DPB1*0202, DPB1*0301, and DPB1*0402, on type 1 diabetes susceptibility (5,7,912). The relative consistency among studies suggests that these alleles represent a useful addition to genetic models of determining type 1 diabetes risk. Whether the DPB1 locus is causally involved in or merely a marker for type 1 diabetes susceptibility, the consistent associations of specific DPB1 alleles with type 1 diabetes susceptibility observed in this and other studies suggest that DPB1 genotyping can be a useful tool to increase the predictive power of genetics for type 1 diabetes susceptibility.

### Mexican-American families.

A total of 84 Mexican-American families (proband plus one or both parents) are included. Control frequencies were determined from AFBACs (affected family-based control subjects) (14). Families were ascertained by the investigators at the Los Angeles County Hospital/University of Southern California Medical School (LAC/USC) and Children’s Hospital of Los Angeles between 1989 and 1993 (7,15,16). Type 1 diabetes was defined according to the National Diabetes Data Group. To be considered of Mexican ancestry, probands had to have a minimum of three of four grandparents born in Mexico. The study was approved by the institutional review board at LAC/USC. Written informed consent was obtained from all subjects and/or their parents before their participation. DPB1 data were previously reported for 42 of these families (7).

### Puerto Rican type 1 diabetic patients and control subjects.

The Puerto Rican registry of children with diabetes was established as part of the World Health Organization’s DiaMond project (17). In 1990, an island-wide registry of new cases of childhood type 1 diabetes was established in Puerto Rico retrospective to 1985. Eligible patients (n = 91) were identified by medical record review at 57 island hospitals that admit pediatric patients. Eligibility criteria included age <15 years at diagnosis, taking insulin at discharge to a Puerto Rican residence, and having a Puerto Rican parent (18). Healthy control subjects (n = 82) from the same area were recruited. Informed consent for sample collection was approved by the institutional review board of the Ponce School of Medicine.

### DAISY.

The DAISY (19) is a prospective study of the natural history of type 1 diabetes, including limited genetic screening and extensive epidemiological data collection. DAISY has two main cohorts, the GPC, ascertained as newborns, and the SOC, ascertained based on having a first-degree relative with type 1 diabetes. Individuals ascertained for the GPC, but having a first-degree relative with type 1 diabetes, were reclassified with the SOC for this study. In the GPC and SOC, 30,951 and 888 subjects were screened, respectively. The highest-risk HLA DR-DQ genotype (DR3/4-DQB1*0302; DR4≠DRB1*0403) was found in 2.3% (n = 713) of GPC and 10.1% (n = 90) of SOC subjects. Sample collection and genotyping for DAISY was done with the approval of the Colorado Multiple Institutional Review Board. The ethnic origin of DAISY subjects is as follows: non-Hispanic white, 60.5%; Hispanic, 23.5%; non-Hispanic black, 6.0%; Asian or Pacific Islander, 1.8%; Amerindian, 0.4%; and other or unknown, 7.8%.

In the DAISY study, SOC individuals with the highest-risk HLA DR-DQ genotype had a far higher risk of developing type 1 diabetes autoimmunity (risk ∼40%) than high-risk GPC individuals (risk ∼7%), suggesting that high-risk SOC individuals may be enriched in non–DR-DQ type 1 diabetes genetic risk factors. A subset of the high type 1 diabetes genetic risk GPC (n = 200) and SOC (n = 50) subjects was selected, without regard to autoantibody or disease status, and genotyped for DPB1. Four GPC samples and three SOC samples were classified as cases, indicating either type 1 diabetes or presence of autoantibodies.

### Genotyping.

Molecular HLA typing data were generated using a linear array that uses the PCR/sequence-specific oligonucleotide probe (SSOP) methodology. DPB1 genotyping by SSOP and linear array technology have been previously described (6,20,21).

### Haplotype estimation.

For Mexican-American families, haplotype phase was determined directly from parent data. Phase was unambiguous in all case subjects. For Puerto Rican samples, maximum likelihood haplotype frequencies were computed using an expectation-maximization algorithm (22) with the Arlequin software program (L. Excoffier, University of Geneva, Switzerland). The SD was computed with 100 bootstrap replicates.

### Statistical methods.

Expected allele frequencies were computed, given LD and haplotype relative penetrances. The null hypothesis (H0) is that DPB1 allele frequencies will differ between patients and control subjects due to 1) LD between DPB1 and DRB1-DQB1 and 2) chance (sampling), consistent with a neutral role for DPB1 polymorphism relative to disease predisposition. Under H0, the expected allele frequencies at DPB1 can be computed using the equation derived by Thomson (14).

${\bar{q}}_{DPj}{=}p_{DP_{j}}{+}\ {{\sum}_{i}^{K}}D_{ij}\ \frac{q_{DR{-}DQi}}{p_{DR{-}DQi}}$

Dij denotes pairwise LD between the ith DR-DQ haplotype and the jth DPB1 allele in the control sample, q denotes frequency in patients, and p denotes frequency in control subjects. This method relies on sampling estimates of pairwise LD between DPB1 and DRB1-DQB1 and on patient and control frequencies derived from the study samples. A sampling error will be associated with the computed value for expected DPB1 allele frequencies; larger control samples lead to smaller sampling errors. This has been taken into account in the statistical tests:

${\chi}^{2}(1\mathrm{df})_{DP_{i}}{=}\ \frac{(o{-}o{^\prime})^{2}}{o{^\prime}}{+}\frac{(e{-}e{^\prime})^{2}}{e{^\prime}}$
$o{=}q_{DPi}\ N_{p};\ e{=}{\bar{q}}_{DPi}\ N_{c};$
$x{=}o{+}e(2)$
$o{^\prime}{=}\ \frac{x.N_{p}}{N_{p}{+}N_{c}};\ e{^\prime}{=}\frac{x.N_{c}}{N_{p}{+}N_{c}}$

For any individual DPi, Np is patient sample size, Nc is control sample size, qDPi is observed frequency of the ith allele in patients, and q′DPi is derived from Eq. 1.

TABLE 1

DPB1 allele frequencies in case subjects (or transmitteds) and control subjects (or AFBACs) in Puerto Rican and Mexican-American populations

DPB1Puerto Rican case and control subjects
Mexican-American simplex families
Control subjects (%)Type 1 diabetic patients (%)χ2P*AFBACs (control) (%)Transmitted to type 1 diabetes (%)χ2P*
0101 15.24 10.44 1.57 NS 2.94 4.76 0.63 NS
0201 8.54 6.04 0.74 NS 13.97 11.90 0.25 NS
0202 0.00 2.20 3.6 0.058 0.74 5.36 4.88 0.027
0301 7.93 16.48 5.08 0.024 6.62 20.24 9.86 0.002
0401 26.22 20.33 1.29 NS 22.06 18.45 0.49 NS
0402 18.29 13.74 1.13 NS 37.50 22.62 5.68 0.017
0501 0.61 1.10 0.24 NS 4.41 4.76 0.02 NS
0601 0.00 0.00 — — 0.00 1.19 1.62 NS
0901 0.00 1.65 2.7 0.1 0.00 0.60 0.81 NS
1001 0.61 1.10 0.24 NS 1.47 0.60 0.58 NS
1101 0.00 0.00 — — 2.21 1.79 0.07 NS
1301 3.66 1.10 2.44 NS 0.00 1.19 1.62 NS
1401 3.66 1.65 1.34 NS 2.21 1.19 0.47 NS
1501 0.00 0.00 — — 0.00 1.19 1.62 NS
1701 1.83 8.24 6.82 0.009 4.41 3.57 0.13 NS
1801 0.61 1.10 0.24 NS 0.74 0.00 1.24 NS
1901 0.00 0.00 — — 0.00 0.60 0.81 NS
2301 0.00 0.00 — — 0.74 0.00 1.24 NS
3301 0.61 1.65 0.8 NS 0.00 0.00 — —
5001 1.83 0.00 3.33 0.068 0.00 0.00 — —
5101 0.61 1.10 0.24 NS 0.00 0.00 — —
5901 0.61 1.10 0.24 NS 0.00 0.00 — —
6601 1.22 0.55 0.45 NS 0.00 0.00 — —
7501 1.83 2.20 0.06 NS 0.00 0.00 — —
Other 6.10 8.24 0.55 NS 0.00 0.00 — —
Total 164 182 33.1 0.023 136 168 32.02 0.015
DPB1Puerto Rican case and control subjects
Mexican-American simplex families
Control subjects (%)Type 1 diabetic patients (%)χ2P*AFBACs (control) (%)Transmitted to type 1 diabetes (%)χ2P*
0101 15.24 10.44 1.57 NS 2.94 4.76 0.63 NS
0201 8.54 6.04 0.74 NS 13.97 11.90 0.25 NS
0202 0.00 2.20 3.6 0.058 0.74 5.36 4.88 0.027
0301 7.93 16.48 5.08 0.024 6.62 20.24 9.86 0.002
0401 26.22 20.33 1.29 NS 22.06 18.45 0.49 NS
0402 18.29 13.74 1.13 NS 37.50 22.62 5.68 0.017
0501 0.61 1.10 0.24 NS 4.41 4.76 0.02 NS
0601 0.00 0.00 — — 0.00 1.19 1.62 NS
0901 0.00 1.65 2.7 0.1 0.00 0.60 0.81 NS
1001 0.61 1.10 0.24 NS 1.47 0.60 0.58 NS
1101 0.00 0.00 — — 2.21 1.79 0.07 NS
1301 3.66 1.10 2.44 NS 0.00 1.19 1.62 NS
1401 3.66 1.65 1.34 NS 2.21 1.19 0.47 NS
1501 0.00 0.00 — — 0.00 1.19 1.62 NS
1701 1.83 8.24 6.82 0.009 4.41 3.57 0.13 NS
1801 0.61 1.10 0.24 NS 0.74 0.00 1.24 NS
1901 0.00 0.00 — — 0.00 0.60 0.81 NS
2301 0.00 0.00 — — 0.74 0.00 1.24 NS
3301 0.61 1.65 0.8 NS 0.00 0.00 — —
5001 1.83 0.00 3.33 0.068 0.00 0.00 — —
5101 0.61 1.10 0.24 NS 0.00 0.00 — —
5901 0.61 1.10 0.24 NS 0.00 0.00 — —
6601 1.22 0.55 0.45 NS 0.00 0.00 — —
7501 1.83 2.20 0.06 NS 0.00 0.00 — —
Other 6.10 8.24 0.55 NS 0.00 0.00 — —
Total 164 182 33.1 0.023 136 168 32.02 0.015
*

Statistically significant P values (≤0.05) are shown in roman text. P values that may be suggestive of a weak association (P > 0.05 but ≤0.10) are shown in italics.

TABLE 2

Normalized LD between DRB1-DQB1 haplotypes and DPB1 alleles

DPB1DRB1-DQB1DP frequency (%)DR-DQ frequency (%)DP-DR-DQ frequency (%)D′χ2P
Puerto Rican control subjects*
0101 0301 0201 13.6 2.0 2.0 1.00 19.31 6 × 10−5
0201 0411 0302 8.8 1.4 0.7 0.45 4.23 0.04
0201 1301 0603 8.8 2.0 1.4 0.63 12.62 0.0004
0301 1302 0604 8.2 3.4 1.4 0.35 6.95 0.008
0401 0101 0501 26.5 6.8 4.1 0.46 6.12 0.013
0401 0307 0201 26.5 2.7 2.0 0.66 4.92 0.03
0401 1104 0301 26.5 2.0 2.0 1.00 8.42 0.0037
0401 1501 0602 26.5 4.8 4.8 1.00 20.22 6 × 10−6
0402 0701 02 17.7 11.6 6.8 0.50 22.19 2.5 × 10−6
0402 1201 0301 17.7 2.0 1.4 0.60 5.01 0.025
1301 0102 0501 4.1 6.1 1.4 0.29 8.00 0.005
AFBACs in Mexican-American samples
0401 0101 0501 22.1 7.3 3.7 0.36 4.90 0.027
0402 0701 02 37.5 11.0 0.7 −0.82 6.84 0.009
0402 0802 0400 37.5 7.3 5.9 0.68 8.32 0.004
0402 0802 0402 37.5 4.4 3.7 0.73 5.63 0.018
0402 1602 0301 37.5 2.9 2.9 1.00 6.87 0.009
DPB1DRB1-DQB1DP frequency (%)DR-DQ frequency (%)DP-DR-DQ frequency (%)D′χ2P
Puerto Rican control subjects*
0101 0301 0201 13.6 2.0 2.0 1.00 19.31 6 × 10−5
0201 0411 0302 8.8 1.4 0.7 0.45 4.23 0.04
0201 1301 0603 8.8 2.0 1.4 0.63 12.62 0.0004
0301 1302 0604 8.2 3.4 1.4 0.35 6.95 0.008
0401 0101 0501 26.5 6.8 4.1 0.46 6.12 0.013
0401 0307 0201 26.5 2.7 2.0 0.66 4.92 0.03
0401 1104 0301 26.5 2.0 2.0 1.00 8.42 0.0037
0401 1501 0602 26.5 4.8 4.8 1.00 20.22 6 × 10−6
0402 0701 02 17.7 11.6 6.8 0.50 22.19 2.5 × 10−6
0402 1201 0301 17.7 2.0 1.4 0.60 5.01 0.025
1301 0102 0501 4.1 6.1 1.4 0.29 8.00 0.005
AFBACs in Mexican-American samples
0401 0101 0501 22.1 7.3 3.7 0.36 4.90 0.027
0402 0701 02 37.5 11.0 0.7 −0.82 6.84 0.009
0402 0802 0400 37.5 7.3 5.9 0.68 8.32 0.004
0402 0802 0402 37.5 4.4 3.7 0.73 5.63 0.018
0402 1602 0301 37.5 2.9 2.9 1.00 6.87 0.009
*

Only haplotypes showing statistically significant LD are shown.

TABLE 3

Observed and expected DPB1 allele frequencies under the hypothesis that differences between case and control subjects are due exclusively to LD with DRB1-DQB1 in Puerto Rican and Mexican-American samples

DPB1Puerto Rican case-control data
Mexican-American family data
Type 1 diabetesχ2P*Type 1 diabetes
χ2P*
Frequency: observed (%)Frequency: expected (%)Observed countsFrequency: observed (%)Frequency: expected (%)Observed counts
0101 10.44 16.17 19 2.15 NS 4.76 2.90 0.663 NS
0201 6.04 8.84 11 0.91 NS 11.90 13.65 20 0.181 NS
0202 2.20 0.00 3.6 0.058 5.36 0.74 4.88 0.027
0301 16.48 8.46 30 4.38 0.036 20.24 6.76 34 9.611 0.002
0401 20.33 27.78 37 2.01 NS 18.45 21.58 31 0.37 NS
0402 13.74 19.77 25 1.89 NS 22.62 38.34 38 6.263 0.012
0501 1.10 0.65 0.2 NS 4.76 4.34 0.03 NS
0601 0.00 0.00 — — 1.19 0.00 1.619 NS
0901 1.65 0.00 2.7 NS 0.60 0.00 0.81 NS
1001 1.10 0.64 0.2 NS 0.60 1.45 0.567 NS
1101 0.00 0.00 — — 1.79 2.19 0.063 NS
1301 1.10 3.86 2.73 NS 1.19 0.00 1.619 NS
1401 1.65 3.79 1.49 NS 1.19 2.21 0.474 NS
1501 0.00 0.00 — — 1.19 0.00 1.619 NS
1701 8.24 1.93 15 6.54 0.011 3.57 4.37 0.122 NS
1801 1.10 0.64 0.2 NS 0.00 0.74 1.236 NS
1901 0.00 0.00 — — 0.60 0.00 0.81 NS
2301 0.00 0.00 — — 0.00 0.74 1.236 NS
3301 1.65 0.64 0.74 NS 0.00 0.00 — —
5001 0.00 1.93 3.51 0.061 0.00 0.00 — —
5101 1.10 0.64 0.2 NS 0.00 0.00 — —
5901 1.10 0.64 0.2 NS 0.00 0.00 — —
6601 0.55 1.30 0.53 NS 0.00 0.00 — —
7501 2.35 1.54 0.2 NS 0.00 0.00 — —
DPB1Puerto Rican case-control data
Mexican-American family data
Type 1 diabetesχ2P*Type 1 diabetes
χ2P*
Frequency: observed (%)Frequency: expected (%)Observed countsFrequency: observed (%)Frequency: expected (%)Observed counts
0101 10.44 16.17 19 2.15 NS 4.76 2.90 0.663 NS
0201 6.04 8.84 11 0.91 NS 11.90 13.65 20 0.181 NS
0202 2.20 0.00 3.6 0.058 5.36 0.74 4.88 0.027
0301 16.48 8.46 30 4.38 0.036 20.24 6.76 34 9.611 0.002
0401 20.33 27.78 37 2.01 NS 18.45 21.58 31 0.37 NS
0402 13.74 19.77 25 1.89 NS 22.62 38.34 38 6.263 0.012
0501 1.10 0.65 0.2 NS 4.76 4.34 0.03 NS
0601 0.00 0.00 — — 1.19 0.00 1.619 NS
0901 1.65 0.00 2.7 NS 0.60 0.00 0.81 NS
1001 1.10 0.64 0.2 NS 0.60 1.45 0.567 NS
1101 0.00 0.00 — — 1.79 2.19 0.063 NS
1301 1.10 3.86 2.73 NS 1.19 0.00 1.619 NS
1401 1.65 3.79 1.49 NS 1.19 2.21 0.474 NS
1501 0.00 0.00 — — 1.19 0.00 1.619 NS
1701 8.24 1.93 15 6.54 0.011 3.57 4.37 0.122 NS
1801 1.10 0.64 0.2 NS 0.00 0.74 1.236 NS
1901 0.00 0.00 — — 0.60 0.00 0.81 NS
2301 0.00 0.00 — — 0.00 0.74 1.236 NS
3301 1.65 0.64 0.74 NS 0.00 0.00 — —
5001 0.00 1.93 3.51 0.061 0.00 0.00 — —
5101 1.10 0.64 0.2 NS 0.00 0.00 — —
5901 1.10 0.64 0.2 NS 0.00 0.00 — —
6601 0.55 1.30 0.53 NS 0.00 0.00 — —
7501 2.35 1.54 0.2 NS 0.00 0.00 — —
*

Statistically significant P values (≤0.05) are shown in roman text. P values that may be suggestive of a weak association (P > 0.05 but ≤0.10) are shown in italics.

TABLE 4

DPB1 allele frequency distribution among DR3/DR4-DQB1*0302 (DR4 ≠ DRB1*0403) samples from DAISY in the GPC and among individuals who have a first-degree relative with type 1 diabetes (SOC)

DPB1All samples combined
Caucasian samples only
GPC frequency (%)SOC frequency (%)χ2P*GPC frequency (%)SOC frequency (%)χ2P*
0101 15.40 15.00 0.01 NS 13.69 14.13 0.01 NS
0201 9.60 12.00 0.48 NS 11.46 11.96 0.01 NS
0202 2.00 1.00 0.45 NS 0.96 0.00 0.88 NS
0301 9.60 17.00 4.21 0.040 9.55 16.30 2.93 0.087
0401 36.20 39.00 0.18 NS 42.36 41.30 0.02 NS
0402 13.60 2.00 9.61 0.002 9.55 1.09 6.68 0.010
0501 0.80 1.00 0.04 NS 1.27 1.09 0.02 NS
0601 4.20 5.00 0.12 NS 4.14 5.43 0.27 NS
1001 0.40 1.00 0.60 NS 0.32 1.09 0.85 NS
1101 0.80 0.00 0.80 NS 0.96 0.00 0.88 NS
1301 0.80 1.00 0.04 NS 0.32 1.09 0.85 NS
1401 2.60 0.00 2.60 NS 1.91 0.00 1.76 NS
1501 0.60 1.00 0.20 NS 0.96 1.09 0.01 NS
1601 0.80 2.00 1.20 NS 0.96 2.17 0.86 NS
1701 1.00 0.00 1.00 NS 0.32 0.00 0.29 NS
Other 1.60 3.00 0.89 NS 1.27 3.26 1.63 NS
Total 500 100 22.44 0.097 314 92 17.95 0.27
DPB1All samples combined
Caucasian samples only
GPC frequency (%)SOC frequency (%)χ2P*GPC frequency (%)SOC frequency (%)χ2P*
0101 15.40 15.00 0.01 NS 13.69 14.13 0.01 NS
0201 9.60 12.00 0.48 NS 11.46 11.96 0.01 NS
0202 2.00 1.00 0.45 NS 0.96 0.00 0.88 NS
0301 9.60 17.00 4.21 0.040 9.55 16.30 2.93 0.087
0401 36.20 39.00 0.18 NS 42.36 41.30 0.02 NS
0402 13.60 2.00 9.61 0.002 9.55 1.09 6.68 0.010
0501 0.80 1.00 0.04 NS 1.27 1.09 0.02 NS
0601 4.20 5.00 0.12 NS 4.14 5.43 0.27 NS
1001 0.40 1.00 0.60 NS 0.32 1.09 0.85 NS
1101 0.80 0.00 0.80 NS 0.96 0.00 0.88 NS
1301 0.80 1.00 0.04 NS 0.32 1.09 0.85 NS
1401 2.60 0.00 2.60 NS 1.91 0.00 1.76 NS
1501 0.60 1.00 0.20 NS 0.96 1.09 0.01 NS
1601 0.80 2.00 1.20 NS 0.96 2.17 0.86 NS
1701 1.00 0.00 1.00 NS 0.32 0.00 0.29 NS
Other 1.60 3.00 0.89 NS 1.27 3.26 1.63 NS
Total 500 100 22.44 0.097 314 92 17.95 0.27

Data are shown for the complete sample set and for the Caucasian subset.

*

Statistically significant P values (≤0.05) are shown in roman text. P values that may be suggestive of weak association (P > 0.05 but ≤0.10) are shown in italics.

Other describes a group of nine alleles, each of which appears fewer than two times in the GPC and SOC combined.

This work was supported by an American Diabetes Association Career Development Award (to J.A.N.), National Institutes of Health (NIH) Grant AI29049 (to H.A.E), a minority supplement to AI29049 (to T.D.C.), NIH Grant DK16722 (to J.A.N.), summer internship support from NIH Grant T35 HL07807 (to T.D.C.), the Cedars-Sinai Board of Governors Chair in Medical Genetics, and the NIH Sponsored Research Program Extramural Associates Development Award 5-G11-HD33674-05 (to A.S.).

The authors thank Catherine Nicklas for excellent technical assistance.

1
Tisch R, McDevitt H: Insulin-dependent diabetes mellitus.
Cell
85
:
291
–297,
1996
2
Pociot F, McDermott MF: Genetics of type 1 diabetes mellitus.
Genes Immun
3
:
235
–249,
2002
3
Raffel LJ, Rotter JI: Type 1 diabetes mellitus. In
Genetic Basis of Common Diseases
. 2nd ed. King RA, Rotter JI, Motulsky AG, Eds. New York, Oxford University Press,
2002
, p.
431
–456
4
Rotter JI, Landaw EM: Measuring the genetic contribution of a single locus to a multilocus disease.
Clin Genet
26
:
529
–542,
1984
5
Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA: The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families.
Am J Hum Genet
59
:
1134
–1148,
1996
6
Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA: The HLA class I A locus affects susceptibility to type 1 diabetes.
Hum Immunol
63
:
657
–664,
2002
7
Erlich HA, Rotter JI, Chang JD, Shaw SD, Raffel LJ, Klitz W, Bugawan TL, Zeidler A: Association of HLA-DPB1*0301 with insulin dependent diabetes mellitus in Mexican-Americans.
Diabetes
45
:
610
–614,
1996
8
Bugawan TL, Klitz W, Alejandrino M, Ching J, Panelo A, Solfelix CM, Petrone A, Buzzetti R, Pozzilli P, Erlich HA: The association of specific HLA class I and II alleles with type 1 diabetes among Filipinos.
Tissue Antigens
59
:
452
–469,
2002
9
Balducci-Silano PL, Layrisse ZE: HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population: associations with other HLA-alleles.
J Autoimmun
8
:
425
–437,
1995
10
Noble JA, Valdes AM, Thomson G, Erlich HA: The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes.
Diabetes
49
:
121
–125,
2000
11
Cucca F, Dudbridge F, Loddo M, Mulargia AP, Lampis R, Angius E, De Virgiliis S, Koeleman BP, Bain SC, Barnett AH, Gilchrist F, Cordell H, Welsh K, Todd JA: The HLA-DPB1–associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1.
Diabetes
50
:
1200
–1205,
2001
12
Johansson S, Lie BA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, Thorsby E, Undlien DE: HLA associations in type 1 diabetes: DPB1 alleles may act as markers of other HLA-complex susceptibility genes.
Tissue Antigens
61
:
344
–351,
2003
13
Lie BA, Akselsen HE, Joner G, Dahl-Jorgensen K, Ronningen KS, Thorsby E, Undlien DE: HLA associations in insulin-dependent diabetes mellitus: no independent association to particular DP genes.
Hum Immunol
55
:
170
–175,
1997
14
Thomson G: HLA DR antigens and susceptibility to insulin-dependent diabetes mellitus.
Am J Hum Genet
36
:
1309
–1317,
1984
15
Vadheim CM, Zeidler A, Rotter JI, Langbaum M, Shulman IA, Spencer MR, Costin G, Riley WJ, Maclaren NK: Different HLA haplotypes in Mexican Americans with IDDM.
Diabetes Care
12
:
497
–500,
1989
16
Erlich HA, Zeidler A, Chang J, Shaw S, Raffel LJ, Klitz W, Beshkov Y, Costin G, Pressman S, Bugawan T, et al.: HLA class II alleles and susceptibility and resistance to insulin dependent diabetes mellitus in Mexican-American families.
Nat Genet
3
:
358
–364,
1993
17
WHO Diamond Project Group: WHO multinational project for childhood diabetes.
Diabetes Care
13
:
1062
–1068,
1990
18
Frazer de Llado TE, Gonzalez de Pijem L, Hawk B: Incidence of IDDM in children living in Puerto Rico: Puerto Rican IDDM Coalition.
Diabetes Care
21
:
744
–746,
1998
19
Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY).
Diabetologia
39
:
807
–812,
1996
20
Bugawan TL, Apple R, Erlich HA: A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes.
Tissue Antigens
44
:
137
–147,
1994
21
Steiner LL, McCurdy DK, Cavalli A, Moonsamy PV, Begovich AB: Two new DPB1 alleles identified in a study of the genetics of susceptibility to pauciarticular juvenile rheumatoid arthritis.
Tissue Antigens
49
:
262
–266,
1997
22
Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.
Mol Biol Evol
12
:
921
–927,
1995